Covid-19 roundup: Ab­bott re­veals new test­ing kit da­ta; An OCD drug shows pos­i­tive signs in mild cas­es

Ab­bott Lab­o­ra­to­ries pro­duced new da­ta Wednes­day morn­ing for one mod­el of its Covid-19 rapid test­ing kits.

The com­pa­ny said it con­duct­ed an in­ter­im read­out of a post-EUA study, eval­u­at­ing its ID NOW tests in a lit­tle over 1,000 pa­tients in ur­gent care clin­ics, hos­pi­tals and nurs­ing homes. Com­pared to lab-based mol­e­c­u­lar PCR tests, Ab­bott’s kits showed an over­all per­for­mance of 93.3% pos­i­tive agree­ment and 98.4% neg­a­tive agree­ment, al­so known as sen­si­tiv­i­ty and speci­fici­ty, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER